Brown medicinal neutral borosilicate glass tube and preparation method thereof
By adding hydroxyapatite, cobalt acetate and sodium fluoroaluminate to the raw materials of brown medicinal neutral borosilicate glass tubes, the component ratio is adjusted, and the problems of high thermal expansion coefficient and poor alkali resistance are solved, and the further improvement is achieved Low linear thermal expansion coefficient and higher alkali resistance expand their application range.
Patent Information
- Application Number
- CN202410804360.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-06-21
AI Technical Summary
The existing brown medicinal neutral borosilicate glass pipeline has a high thermal expansion coefficient and poor alkali resistance, which limits its use range.
By adding hydroxyapatite and cobalt acetate to the raw materials and adding sodium fluoroaluminate on the basis of it, the weight ratio is adjusted to enhance the tetrahedral network structure in the glass and improve the O/Si ratio, reduce the linear thermal expansion coefficient and improve the Alkaline resistance.
It effectively reduces the linear thermal expansion coefficient of brown medicinal neutral borosilicate glass tubes, improves its alkali resistance, and reaches the level 1 standard, meeting a wider use requirement.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of glass materials, and in particular to a brown medicinal neutral borosilicate glass tube and a preparation method thereof. Background Art
[0002] Brown pharmaceutical glass tubes, as a common pharmaceutical packaging material, play an important role in the pharmaceutical packaging industry due to their ability to effectively block light and protect drugs from damage. According to the difference in chemical composition, brown pharmaceutical glass tubes can be divided into brown pharmaceutical low borosilicate glass tubes, brown pharmaceutical sodium calcium borosilicate glass tubes and brown pharmaceutical neutral borosilicate glass tubes. Compared with the former two, brown pharmaceutical neutral borosilicate glass tubes are favored by the market because of their excellent temperature difference resistance, excellent anti-burst ability and excellent impact resistance.
[0003] However, the existing brown neutral borosilicate glass tube for pharmaceutical use has a high coefficient of linear thermal expansion and poor alkali resistance, which seriously limits its scope of use. Therefore, in order to expand the use scenarios and meet market demand, it is of great significance to develop a new type of brown neutral borosilicate glass tube for pharmaceutical use. Summary of the invention
[0004] The invention provides a brown medicinal neutral borosilicate glass tube and a preparation method thereof, which solves the problems of high thermal expansion coefficient and poor alkali resistance of the brown medicinal neutral borosilicate glass tube in the related art.
[0005] The technical solution of the present invention is as follows:
[0006] The invention provides a brown medicinal neutral borosilicate glass tube. The raw materials include the following components in parts by weight: 70-80 parts of quartz sand, 15-25 parts of borax, 1-3 parts of aluminum hydroxide, 6-10 parts of spodumene, 1-10 parts of hydroxyapatite, 1-3 parts of cobalt acetate, 0.2-0.4 parts of iron oxide, 1-2 parts of sulfur and 0.5-1 parts of carbon powder.
[0007] As a further technical solution, the weight ratio of the hydroxyapatite to cobalt acetate is 2-3:1.
[0008] In the present invention, when the weight ratio of hydroxyapatite to cobalt acetate is 2 to 3:1, it helps to further reduce the linear thermal expansion coefficient of the brown medicinal neutral borosilicate glass tube and further improve its alkali resistance.
[0009] As a further technical solution, the raw materials also include 1 to 3 parts of sodium fluoroaluminate.
[0010] In the present invention, in order to reduce the linear thermal expansion coefficient of the brown medicinal neutral borosilicate glass tube and improve its alkali resistance, hydroxyapatite is added to the raw material. The inventors found that on the basis of the hydroxyapatite contained in the raw material, the addition of sodium fluoroaluminate can further enhance the tetrahedral network structure in the glass, further reduce the linear thermal expansion coefficient of the brown medicinal neutral borosilicate glass tube, and further improve its alkali resistance.
[0011] As a further technical solution, the weight ratio of the hydroxyapatite to sodium fluoroaluminate is 2-3:1.
[0012] In the present invention, when the weight ratio of hydroxyapatite to sodium fluoroaluminate is 2 to 3:1, it helps to further reduce the linear thermal expansion coefficient of the brown medicinal neutral borosilicate glass tube and further improve its alkali resistance.
[0013] As a further technical solution, the quartz sand is composed of the following components in weight percentage: aluminum oxide 0.1%~0.2%, iron oxide 0.01%~0.02%, potassium oxide 0.02%~0.03%, calcium oxide ≤0.015%, sodium oxide ≤0.015%, magnesium oxide ≤0.015%, and the rest is silicon dioxide.
[0014] As a further technical solution, the borax is composed of the following components in weight percentage: carbonate ≤0.2%, sulfate ≤0.2%, chloride ≤0.03%, and the rest is sodium tetraborate.
[0015] As a further technical solution, the spodumene is composed of the following components in weight percentage: 23% to 25% aluminum oxide, 7% to 8% lithium oxide, 0.2% to 0.3% sodium oxide, 0.1% to 0.2% potassium oxide, and the rest is silicon dioxide.
[0016] The present invention also provides a method for preparing the brown medicinal neutral borosilicate glass tube, comprising the following steps:
[0017] S1, mixing the raw materials uniformly, melting them, and obtaining glass liquid;
[0018] S2. After the glass liquid is clarified, homogenized and drawn into shape, a brown medicinal neutral borosilicate glass tube is obtained.
[0019] As a further technical solution, in step S1, during the melting, the temperature is 1550-1580°C and the time is 4-5 hours.
[0020] As a further technical solution, in step S2, during the clarification, the temperature is 1580-1620°C and the time is 1-2 hours.
[0021] As a further technical solution, in step S2, during the homogenization, the temperature is 1560°C~1580°C and the time is 20~30 minutes.
[0022] As a further technical solution, in step S2, the temperature during the drawing is 1050-1080°C.
[0023] The working principle and beneficial effects of the present invention are:
[0024] In the present invention, the raw materials of the brown medicinal neutral borosilicate glass tube include hydroxyapatite and cobalt acetate. By using the two together, on the one hand, the tetrahedral network structure in the glass can be enhanced, and on the other hand, the O / Si ratio of the glass structure can be increased, thereby improving the stability during the processing, thereby reducing the linear thermal expansion coefficient of the brown medicinal neutral borosilicate glass tube and improving its alkali resistance. DETAILED DESCRIPTION
[0025] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0026] In the following examples and comparative examples, unless otherwise specified, the quartz sand is composed of the following components in weight percentage: 0.1% aluminum oxide, 0.02% iron oxide, 0.03% potassium oxide, 0.013% calcium oxide, 0.015% sodium oxide, 0.014% magnesium oxide, and the remainder is silicon dioxide;
[0027] Borax is composed of the following components in percentage by weight: carbonate 0.15%, sulfate 0.18%, chloride 0.02%, and the remainder sodium tetraborate;
[0028] Spodumene is composed of the following components in weight percentage: 24.5% aluminum oxide, 7.5% lithium oxide, 0.3% sodium oxide, 0.1% potassium oxide, and the rest is silicon dioxide.
[0029] Example 1
[0030] A method for preparing a brown medicinal neutral borosilicate glass tube comprises the following steps:
[0031] S1. By weight, 70 parts of quartz sand, 15 parts of borax, 1 part of aluminum hydroxide, 6 parts of spodumene, 1 part of hydroxyapatite, 1 part of cobalt acetate, 0.2 parts of iron oxide, 1 part of sulfur and 0.5 parts of carbon powder were mixed evenly, and melted at 1550° C. for 5 hours to obtain glass liquid;
[0032] S2. After the glass liquid is clarified at 1580°C for 2 hours, it is homogenized at 1560°C for 30 minutes and then drawn into shape at 1050°C to obtain a brown pharmaceutical neutral borosilicate glass tube.
[0033] Example 2
[0034] A method for preparing a brown medicinal neutral borosilicate glass tube comprises the following steps:
[0035] S1. By weight, 80 parts of quartz sand, 25 parts of borax, 3 parts of aluminum hydroxide, 10 parts of spodumene, 10 parts of hydroxyapatite, 3 parts of cobalt acetate, 0.4 parts of iron oxide, 2 parts of sulfur and 1 part of carbon powder were mixed evenly, and melted at 1580° C. for 4 hours to obtain glass liquid;
[0036] S2. After the glass liquid is clarified at 1620°C for 1 hour, it is homogenized at 1580°C for 20 minutes and then drawn into shape at 1080°C to obtain a brown pharmaceutical neutral borosilicate glass tube.
[0037] Example 3
[0038] A method for preparing a brown medicinal neutral borosilicate glass tube comprises the following steps:
[0039] S1. By weight, 75 parts of quartz sand, 20 parts of borax, 2 parts of aluminum hydroxide, 8 parts of spodumene, 5 parts of hydroxyapatite, 1 part of cobalt acetate, 0.3 parts of iron oxide, 1.5 parts of sulfur and 0.8 parts of carbon powder were mixed evenly, and melted at 1580° C. for 4 hours to obtain glass liquid;
[0040] S2. After the glass liquid is clarified at 1620°C for 1 hour, it is homogenized at 1580°C for 20 minutes and then drawn into shape at 1080°C to obtain a brown pharmaceutical neutral borosilicate glass tube.
[0041] Example 4
[0042] The only difference between this embodiment and embodiment 3 is that, in this embodiment, the weight parts of hydroxyapatite are 3 parts and the weight parts of cobalt acetate are 3 parts.
[0043] Example 5
[0044] The only difference between this embodiment and embodiment 3 is that, in this embodiment, the weight parts of hydroxyapatite are 4 parts and the weight parts of cobalt acetate are 2 parts.
[0045] Example 6
[0046] The only difference between this embodiment and embodiment 3 is that, in this embodiment, the weight portion of hydroxyapatite is 4.5 parts, and the weight portion of cobalt acetate is 1.5 parts.
[0047] Example 7
[0048] The only difference between this embodiment and embodiment 6 is that in this embodiment, 1 part of sodium fluoroaluminate is also added.
[0049] Example 8
[0050] The only difference between this embodiment and embodiment 7 is that, in this embodiment, the weight portion of sodium fluoroaluminate is 3 parts.
[0051] Example 9
[0052] The only difference between this embodiment and embodiment 7 is that, in this embodiment, the weight portion of sodium fluoroaluminate is 2.25 parts.
[0053] Example 10
[0054] The only difference between this embodiment and embodiment 7 is that, in this embodiment, the weight portion of sodium fluoroaluminate is 1.5 parts.
[0055] Comparative Example 1
[0056] The difference between this comparative example and Example 1 is that in this comparative example, hydroxyapatite is not added and the weight portion of cobalt acetate added is 2 parts.
[0057] Comparative Example 2
[0058] The difference between this comparative example and Example 1 is that in this comparative example, cobalt acetate is not added and the weight portion of hydroxyapatite added is 2 parts.
[0059] Comparative Example 3
[0060] The only difference between this comparative example and Example 1 is that in this comparative example, cobalt acetate and hydroxyapatite are not added.
[0061] Comparative Example 4
[0062] The only difference between this comparative example and Example 7 is that in this comparative example, hydroxyapatite is not added.
[0063] The transmittance of the brown medicinal neutral borosilicate glass tubes prepared in Examples 1 to 10 at 313 nm was tested using a glass optical transmittance detector (model NS13A), and the transmittance was 5% to 8%, which indicates that the brown medicinal neutral borosilicate glass tubes prepared by the present invention have excellent light-shielding ability and can meet the needs of the pharmaceutical packaging market.
[0064] The brown medicinal neutral borosilicate glass tubes prepared in Examples 1 to 10 and Comparative Examples 1 to 4 were subjected to the following performance tests:
[0065] ①Linear thermal expansion coefficient: measured using a push rod glass bottle linear expansion coefficient tester (model ZRPY-III-1000) in accordance with ASTM E228-2017 standard;
[0066] ②Alkali resistance: According to YBB00352004-2015 "Determination of glass resistance to corrosion by boiling mixed alkali aqueous solution", the mass lost per unit surface area after testing for 3 hours.
[0067] The test results are shown in Table 1 below.
[0068] Table 1 Performance test results
[0069]
[0070] The comparison between Example 1 and Comparative Examples 1 to 3 shows that, when preparing a brown pharmaceutical neutral borosilicate glass tube, the linear thermal expansion coefficient of the brown pharmaceutical neutral borosilicate glass tube can be reduced by using hydroxyapatite and cobalt acetate in combination, and its alkali resistance can be improved to reach the Class 1 standard. The comparison between Examples 6 to 7 and Comparative Example 4 shows that, on the basis of hydroxyapatite in the raw material, the addition of sodium fluoroaluminate helps to further reduce the linear thermal expansion coefficient of the brown pharmaceutical neutral borosilicate glass tube and further improve its alkali resistance.
[0071] Comparison between Examples 3-4 and 5-6 shows that when the weight ratio of hydroxyapatite to cobalt acetate is 2-3:1, it helps to further reduce the linear thermal expansion coefficient of the brown pharmaceutical neutral borosilicate glass tube and further improve its alkali resistance. Comparison between Examples 7-8 and 9-10 shows that when the weight ratio of hydroxyapatite to sodium fluoroaluminate is 2-3:1, it helps to further reduce the linear thermal expansion coefficient of the brown pharmaceutical neutral borosilicate glass tube and further improve its alkali resistance.
[0072] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A brown neutral borosilicate glass tube for pharmaceutical use, characterized in that: The raw materials include the following components in parts by weight: 70-80 parts of quartz sand, 15-25 parts of borax, 1-3 parts of aluminum hydroxide, 6-10 parts of spodumene, 1-10 parts of hydroxyapatite, 1-3 parts of cobalt acetate, 0.2-0.4 parts of iron oxide, 1-2 parts of sulfur, and 0.5-1 parts of carbon powder; The weight ratio of the hydroxyapatite to cobalt acetate is 2-3:1; The raw materials also include 1 to 3 parts of sodium fluoroaluminate.
2. A brown medicinal neutral borosilicate glass tube according to claim 1, characterized in that: The weight ratio of the hydroxyapatite to sodium fluoroaluminate is 2-3:
1.
3. A brown medicinal neutral borosilicate glass tube according to claim 1, characterized in that: The quartz sand is composed of the following components in weight percentage: 0.1% to 0.2% aluminum oxide, 0.01% to 0.02% iron oxide, 0.02% to 0.03% potassium oxide, ≤0.015% calcium oxide, ≤0.015% sodium oxide, ≤0.015% magnesium oxide, and the rest is silicon dioxide.
4. A brown neutral borosilicate glass tube for pharmaceutical use according to claim 1, characterized in that: The borax is composed of the following components in weight percentage: carbonate ≤0.2%, sulfate ≤0.2%, chloride ≤0.03%, and the rest is sodium tetraborate.
5. A brown medicinal neutral borosilicate glass tube according to claim 1, characterized in that: The spodumene is composed of the following components in weight percentage: 23% to 25% aluminum oxide, 7% to 8% lithium oxide, 0.2% to 0.3% sodium oxide, 0.1% to 0.2% potassium oxide, and the rest is silicon dioxide.
6. A method for preparing a brown neutral borosilicate glass tube for pharmaceutical use as claimed in any one of claims 1 to 5, characterized in that: The following steps are involved: S1, mixing the raw materials uniformly, melting them, and obtaining glass liquid; S2. After the glass liquid is clarified, homogenized and drawn into shape, a brown medicinal neutral borosilicate glass tube is obtained.
7. The method for preparing a brown neutral borosilicate glass tube for pharmaceutical use according to claim 6, characterized in that: In step S1, during the melting, the temperature is 1550-1580° C. and the time is 4-5 hours.
8. The method for preparing a brown medicinal neutral borosilicate glass tube according to claim 6, characterized in that: In step S2, the temperature during the drawing process is 1050-1080°C.
